Brilinta is an oral antiplatelet drug that is used with low dose aspirin to decrease the risk of myocardial infarction (heart attack) and stroke in patients with acute coronary syndrome.
A heart attack happens when one or more of the arteries that supply blood to heart gets blocked. Due to this heart does not get enough oxygen that it needs to function. With the right medications and lifestyle changes, one can reduce the risk of another heart attack or stroke. Platelet (blood cells) P2Y12 receptors play a key role in platelet activation and thrombus (clot) formation. Platelets can gather and stick together to form another clot in artery causing another heart attack. After the plaque ruptures, Brilinta helps stop platelets from reacting and forming a new and dangerous clot that could cause another heart attack.
Brilinta is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Brilinta also reduces the rate of stent thrombosis in patients who have undergone treatment of ACS.
Brilinta is a brand from AstraZeneca a global, science-led biopharmaceutical company. The company’s innovative medicines are used by millions of patients worldwide. AstraZeneca is considered as one of the 100 Most Sustainable Corporations in the world.